Literature DB >> 11931540

Rabeprazole: quest for the best PPI.

Kentaro Sugano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11931540     DOI： 10.1007/s005350200028

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  13 in total

1.  Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.

Authors:  M Besancon; A Simon; G Sachs; J M Shin
Journal:  J Biol Chem       Date:  1997-09-05       Impact factor: 5.157

2.  Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.

Authors:  C P Dekkers; J A Beker; B Thjodleifsson; A Gabryelewicz; N E Bell; T J Humphries
Journal:  Aliment Pharmacol Ther       Date:  1999-01       Impact factor: 8.171

3.  Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.

Authors:  J P Galmiche; F Zerbib; P Ducrottè; J Fournet; P Rampal; N Avasthy; T J Humphries
Journal:  Aliment Pharmacol Ther       Date:  2001-09       Impact factor: 8.171

Review 4.  Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.

Authors:  T Ishizaki; Y Horai
Journal:  Aliment Pharmacol Ther       Date:  1999-08       Impact factor: 8.171

5.  Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.

Authors:  J C Delchier; G Cohen; T J Humphries
Journal:  Scand J Gastroenterol       Date:  2000-12       Impact factor: 2.423

Review 6.  Proton pump inhibitors and their drug interactions: an evidence-based approach.

Authors:  L B Gerson; G Triadafilopoulos
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 2.566

7.  Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.

Authors:  C P Dekkers; J A Beker; B Thjodleifsson; A Gabryelewicz; N E Bell; T J Humphries
Journal:  Aliment Pharmacol Ther       Date:  1999-02       Impact factor: 8.171

8.  Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators.

Authors:  P J Kahrilas; G W Falk; D A Johnson; C Schmitt; D W Collins; J Whipple; D D'Amico; B Hamelin; B Joelsson
Journal:  Aliment Pharmacol Ther       Date:  2000-10       Impact factor: 8.171

9.  Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group.

Authors:  C P Dekkers; J A Beker; B Thjodleifsson; A Gabryelewicz; N E Bell; T J Humphries
Journal:  Aliment Pharmacol Ther       Date:  1998-08       Impact factor: 8.171

10.  A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.

Authors:  M P Williams; J Sercombe; M I Hamilton; R E Pounder
Journal:  Aliment Pharmacol Ther       Date:  1998-11       Impact factor: 8.171
View more
  1 in total

1.  Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers.

Authors:  Yongqing Wang; Yaozong Yuan; Ling Meng; Hongwei Fan; Jianming Xu; Hongwen Zhang; Meifeng Wang; Hongyu Yuan; Ning Ou; Haibo Zhang; Yang Chao; Ruihua Shi
Journal:  Eur J Clin Pharmacol       Date:  2010-11-26       Impact factor: 2.953
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.